Unknown

Dataset Information

0

A TRAIL-Delivered Lipoprotein-Bioinspired Nanovector Engineering Stem Cell-Based Platform for Inhibition of Lung Metastasis of Melanoma.


ABSTRACT: Genetically engineered mesenchymal stem cells (MSCs), as non-viral gene delivery platforms, are rapidly evolving in tumor therapy due to their low immunogenicity and natural tumor-homing capacity. Methods: In this paper, we selected reconstituted high-density lipoprotein (rHDL), a lipoprotein-bioinspired nanovector with specific binding ability to scavenger receptor B type I (SR-BI) expressed on MSCs, as a transfection agent to genetically modify MSCs. pDNA encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was used as a functional gene to be transfected into the nucleus of MSCs for TRAIL expression. Lauric acid-coupled polyethyleneimine (PEI-LA) as an amphiphilic cationic polymer was synthesized to electrostatically bind to pDNA, and then incorporated into rHDL to form rHDL/PEI-LA/pDNA nanoparticles. Results: The nanoparticles exhibited homogenous particle size and excellent serum stability in vitro. Meanwhile, this SR-BI-targeted rHDL performed efficient intracellular gene delivery, specific lysosome-independent mechanism of cellular uptake and high transfection of pDNA towards MSCs. Moreover, high TRAIL expression in MSCs was detected after rHDL-mediated transfection. In vitro and in vivo results indicated that genetically engineered MSCs could accurately target to B16F10 cells, thereby producing significant apoptosis-inducing effect on aggressive melanoma. Conclusion: TRAIL-expressing MSCs engineered by rHDL nanovector was an efficient and hypotoxic method for stem cells-based pulmonary melanoma metastasis-targeting therapy.

SUBMITTER: Chen K 

PROVIDER: S-EPMC6568176 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

A TRAIL-Delivered Lipoprotein-Bioinspired Nanovector Engineering Stem Cell-Based Platform for Inhibition of Lung Metastasis of Melanoma.

Chen Kerong K   Cao Xiaoqing X   Li Min M   Su Yujie Y   Li Huipeng H   Xie Mengying M   Zhang Ziqi Z   Gao Hongbin H   Xu Xiangting X   Han Yi Y   Zhou Jianping J   Wang Wei W  

Theranostics 20190509 10


Genetically engineered mesenchymal stem cells (MSCs), as non-viral gene delivery platforms, are rapidly evolving in tumor therapy due to their low immunogenicity and natural tumor-homing capacity. <b>Methods:</b> In this paper, we selected reconstituted high-density lipoprotein (rHDL), a lipoprotein-bioinspired nanovector with specific binding ability to scavenger receptor B type I (SR-BI) expressed on MSCs, as a transfection agent to genetically modify MSCs. pDNA encoding tumor necrosis factor  ...[more]

Similar Datasets

| S-EPMC7455490 | biostudies-literature
| S-EPMC6224335 | biostudies-literature
| S-EPMC4311262 | biostudies-literature
| S-EPMC4070218 | biostudies-literature
| S-EPMC7792954 | biostudies-literature
| S-EPMC6456988 | biostudies-literature
| S-EPMC4630637 | biostudies-literature
| S-EPMC6403759 | biostudies-literature
| S-EPMC5663367 | biostudies-literature
| S-EPMC11014651 | biostudies-literature